Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Anthony A Estrada"'
Autor:
Ernie Yulyaningsih, Jung H Suh, Melania Fanok, Roni Chau, Hilda Solanoy, Ryan Takahashi, Anna I Bakardjiev, Isabel Becerra, N Butch Benitez, Chi-Lu Chiu, Sonnet S Davis, William E Dowdle, Timothy Earr, Anthony A Estrada, Audrey Gill, Connie Ha, Patrick CG Haddick, Kirk R Henne, Martin Larhammar, Amy W-S Leung, Romeo Maciuca, Bahram Memarzadeh, Hoang N Nguyen, Alicia A Nugent, Maksim Osipov, Yingqing Ran, Kevin Rebadulla, Elysia Roche, Thomas Sandmann, Jing Wang, Joseph W Lewcock, Kimberly Scearce-Levie, Lesley A Kane, Pascal E Sanchez
Publikováno v:
eLife, Vol 12 (2024)
The integrated stress response (ISR) is a conserved pathway in eukaryotic cells that is activated in response to multiple sources of cellular stress. Although acute activation of this pathway restores cellular homeostasis, intense or prolonged ISR ac
Externí odkaz:
https://doaj.org/article/6521500dd1424027bebffc6920eba56b
Autor:
Maurits F. J. M. Vissers, Jules A. A. C. Heuberger, Geert Jan Groeneveld, Jerome Oude Nijhuis, Peter Paul De Deyn, Salah Hadi, Jeffrey Harris, Richard M. Tsai, Andres Cruz‐Herranz, Fen Huang, Vincent Tong, Rebecca Erickson, Yuda Zhu, Kimberly Scearce‐Levie, Jennifer Hsiao‐Nakamoto, Xinyan Tang, Megan Chang, Brian M. Fox, Anthony A. Estrada, Robert J. Pomponio, Miguel Alonso‐Alonso, Moshe Zilberstein, Nazem Atassi, Matthew D. Troyer, Carole Ho
Publikováno v:
Clinical and Translational Science, Vol 15, Iss 8, Pp 2010-2023 (2022)
Abstract RIPK1 is a master regulator of inflammatory signaling and cell death and increased RIPK1 activity is observed in human diseases, including Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS). RIPK1 inhibition has been shown to
Externí odkaz:
https://doaj.org/article/b9ff23b0f0ad4f13a0f534eb7f32e626
Autor:
Scarlett J Barker, Mai B Thayer, Chaeyoung Kim, David Tatarakis, Matthew Simon, Rebekah L Dial, Lizanne Nilewski, Robert C Wells, Yinhan Zhou, Megan Afetian, Alfred Chappell, Kylie S Chew, Johann Chow, Allisa Clemens, Claire B Discenza, Jason Dugas, Chrissa Dwyer, Timothy Earr, Connie Ha, David Huynh, Srini Jayaraman, Wanda Kwan, Cathal Mahon, Michelle Pizzo, Elysia Roche, Laura Sanders, Alexander Stergioulis, Raymond Tong, Hai Tran, Joy Zuchero, Anthony A Estrada, Kapil Gadkar, Christopher MM Koth, Pascal E Sanchez, Robert G Thorne, Ryan J Watts, Thomas Sandmann, Lesley Kane, Frank Rigo, Mark S Dennis, Joseph W Lewcock, Sarah L DeVos
Antisense oligonucleotides (ASO) are promising therapies for neurological disorders, though they are unable to cross the blood-brain barrier (BBB) and must be delivered directly to the central nervous system (CNS). Here, we use a human transferrin re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::56046f97df89d6a2d15a721b2fca4f31
https://doi.org/10.1101/2023.04.25.538145
https://doi.org/10.1101/2023.04.25.538145
Autor:
Michael T. Maloney, Xiang Wang, Rajarshi Ghosh, Shan V. Andrews, Romeo Maciuca, Shababa T. Masoud, Richard M. Caprioli, John Chen, Chi-Lu Chiu, Sonnet S. Davis, Audrey Cheuk-Nga Ho, Hoang N. Nguyen, Nicholas E. Propson, Michelle L. Reyzer, Oliver B. Davis, Matthew C. Deen, Sha Zhu, Gilbert Di Paolo, David J. Vocadlo, Anthony A. Estrada, Javier de Vicente, Joseph W. Lewcock, Annie Arguello, Jung H. Suh, Sarah Huntwork-Rodriguez, Anastasia G. Henry
Lysosomal dysfunction is a hallmark of Parkinson’s disease (PD), and variants in several PD-associated genes, includingLRRK2, perturb lysosomal homeostasis. Based on this, LRRK2 kinase inhibition is being explored as a therapeutic approach for the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dc13473cd36348881c86cb13ff023e4d
https://doi.org/10.1101/2022.12.19.521070
https://doi.org/10.1101/2022.12.19.521070
Autor:
Danna Jennings, Sarah Huntwork-Rodriguez, Anastasia G. Henry, Jennifer C. Sasaki, René Meisner, Dolores Diaz, Hilda Solanoy, Xiang Wang, Elvira Negrou, Vitaliy V. Bondar, Rajarshi Ghosh, Michael T. Maloney, Nicholas E. Propson, Yuda Zhu, Romeo D. Maciuca, Laura Harris, Angela Kay, Peter LeWitt, T. Alex King, Drew Kern, Aaron Ellenbogen, Ira Goodman, Andrew Siderowf, Jason Aldred, Omid Omidvar, Shababa T. Masoud, Sonnet S. Davis, Annie Arguello, Anthony A. Estrada, Javier de Vicente, Zachary K. Sweeney, Giuseppe Astarita, Marie T. Borin, Bradley K. Wong, Harvey Wong, Hoang Nguyen, Kimberly Scearce-Levie, Carole Ho, Matthew D. Troyer
Publikováno v:
Science Translational Medicine. 14
Mutations in leucine-rich repeat kinase 2 ( LRRK2 ) are the most common genetic risk factors for Parkinson’s disease (PD). Increased LRRK2 kinase activity is thought to impair lysosomal function and may contribute to the pathogenesis of PD. Thus, i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12d447b718b56152fa35afc4ad299bcf
https://doi.org/10.1126/scitranslmed.abj2658
https://doi.org/10.1126/scitranslmed.abj2658
Autor:
Daniel G. Shore, Andrew D. Medhurst, Zachary Kevin Sweeney, Xingrong Liu, Andrew W. Gill, Edward G. McIver, John Moffat, Jason Drummond, Alan Beresford, Bryan K. Chan, Tracy Kleinheinz, Haitao Zhu, Huifen Chen, Anthony A. Estrada
Publikováno v:
Bioorganicmedicinal chemistry letters. 29(4)
The discovery of disease-modifying therapies for Parkinson’s Disease (PD) represents a critical need in neurodegenerative medicine. Genetic mutations in LRRK2 are risk factors for the development of PD, and some of these mutations have been linked
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::037486ba107ae90cb34b8b5dd9f63986
https://pubmed.ncbi.nlm.nih.gov/30522953
https://pubmed.ncbi.nlm.nih.gov/30522953
Publikováno v:
Tetrahedron Letters. 56:4063-4066
A practical method for the Minisci reaction of electron-deficient pyrimidines with carboxylic acids is described. The one-step protocol allows for the alkylation of halo- and trifluoromethyl pyrimidines with a variety of readily available alkyl and (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::484a51b5c72b6a48e6e18180bf25ac7d
https://doi.org/10.1016/j.tetlet.2015.04.123
https://doi.org/10.1016/j.tetlet.2015.04.123
Publikováno v:
Journal of Medicinal Chemistry. 58:6733-6746
There is an urgent need for the development of Parkinson’s disease (PD) treatments that can slow disease progression. The leucine-rich repeat kinase 2 (LRRK2) protein has been genetically and functionally linked to PD, and modulation of LRRK2 enzym
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9f6d74c1adf45afb92fb35ec7267b9d9
https://doi.org/10.1021/acs.jmedchem.5b00261
https://doi.org/10.1021/acs.jmedchem.5b00261
Autor:
Amy Gustafson, Michael Siu, Reina N. Fuji, Anthony A. Estrada, Jinhua Chen, Jianping Yin, Gauri Deshmukh, Yichin Liu, Seth F. Harris, Jose Imperio, Rebecca Erickson, William J. Meilandt, Changyou Ma, Snahel Patel, Joseph P. Lyssikatos, Paul Gibbons, Wendy Liu, Xingrong Liu, Joseph W. Lewcock
Publikováno v:
Journal of medicinal chemistry. 60(19)
Significant data exists to suggest that dual leucine zipper kinase (DLK, MAP3K12) is a conserved regulator of neuronal degeneration following neuronal injury and in chronic neurodegenerative disease. Consequently, there is considerable interest in th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9eef807727b6c9e2cd49383f0d8faf26
https://pubmed.ncbi.nlm.nih.gov/28929759
https://pubmed.ncbi.nlm.nih.gov/28929759
Autor:
Yichin Liu, Frederick Cohen, Bei Wang, Joseph W. Lewcock, Kimberly L. Stark, Brian Dean, Young G. Shin, Arundhati Sengupta Ghosh, Kelly De La Torre, Paul Gibbons, Joseph P. Lyssikatos, Claire E. Le Pichon, Wendy Liu, Jian Wang, Michael Siu, Xingrong Liu, Snahel Patel, Malcolm P. Huestis, Han Lin, Changyou Ma, Amy Gustafson, Anthony A. Estrada, Gauri Deshmukh, Xianrui Zhao, Kimberly Scearce-Levie, Cuong Ly, Hilda Solanoy
Publikováno v:
Journal of Medicinal Chemistry. 58:401-418
Dual leucine zipper kinase (DLK, MAP3K12) was recently identified as an essential regulator of neuronal degeneration in multiple contexts. Here we describe the generation of potent and selective DLK inhibitors starting from a high-throughput screenin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d79efe4ad303e722a20a7b244525eeda
https://doi.org/10.1021/jm5013984
https://doi.org/10.1021/jm5013984